Stockscreener 앱 받기
9.29
2.09%
0.19
시간 외 거래:
9.47
0.18
+1.94%
전일 마감가:
$9.10
열려 있는:
$9.1
하루 거래량:
975.58K
Relative Volume:
0.97
시가총액:
$904.31M
수익:
$1.91M
순이익/손실:
$-94.23M
주가수익비율:
-3.6424
EPS:
-2.5505
순현금흐름:
$-79.76M
1주 성능:
+2.31%
1개월 성능:
+46.07%
6개월 성능:
+122.25%
1년 성능:
+100.65%
1일 변동 폭
$9.02
$9.49
1주일 범위
$8.43
$9.49
52주 변동 폭
$2.85
$9.79
Anteris Technologies Global Corp Stock (AVR) Company Profile
명칭
Anteris Technologies Global Corp
전화
651-493-0606
주소
860 BLUE GENTIAN ROAD, EAGAN
Compare AVR vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
9.29 | 885.81M | 1.91M | -94.23M | -79.76M | -2.5505 |
ISRG
Intuitive Surgical Inc
|
402.30 | 146.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.43 | 40.04B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.28 | 32.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.19 | 30.23B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
182.82 | 27.04B | 5.54B | 1.52B | 1.74B | 10.37 |
Anteris Technologies Global Corp Stock (AVR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | Cantor Fitzgerald | Overweight |
| 2026-03-11 | 개시 | Wells Fargo | Overweight |
| 2025-01-08 | 개시 | Lake Street | Buy |
| 2025-01-07 | 개시 | Barclays | Overweight |
| 2025-01-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-07 | 개시 | TD Cowen | Buy |
모두보기
Anteris Technologies Global Corp 주식(AVR)의 최신 뉴스
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL), Cogent Biosciences (COGT) and Anteris Technologies Global Corp. (AVR) - The Globe and Mail
Anteris (NASDAQ: AVR) signs $250M at-the-market sales agreement with TD Cowen - Stock Titan
ChartWatch ASX scans: Brazilian Rare Earths, Echoiq, Weebit Nano, Anteris Technologies, Global X Semiconductor ETF - MSN
Anteris Technologies Global Corp plans to issue up to $250 million in common stock through TD Cowen as the underwriter. - Bitget
Anteris Technologies Global Launches $250 Million ATM Offering Under Sales Agreement With TD Cowen - TradingView
Anteris (NASDAQ: AVR) launches $250M at-the-market share program - Stock Titan
Anteris Technologies (NASDAQ: AVR) establishes $250M ATM with TD Cowen - Stock Titan
ChartWatch ASX Scans: Brazilian Rare Earths, Echoiq, Weebit Nano. Anteris Technologies, Global X Semiconductor ETF - Market Index
Anteris Technologies Global : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Director Susan Knight reports initial insider status at Anteris (NASDAQ: AVR) - Stock Titan
Number of shareholders of Anteris Technologies Global Corp. – NASDAQ:AVR - TradingView
Stephen Denaro details indirect Anteris (AVR) share and option holdings - Stock Titan
Nantahala holds 6,143,154 shares of Anteris (AVR) as of 03/31/2026 - Stock Titan
AVR Maintained by Barclays -- Price Target Raised to $18.00 - GuruFocus
We Think Anteris Technologies Global (ASX:AVR) Can Afford To Drive Business Growth - simplywall.st
Anteris Technologies Global Corp. (AVR) Gets a Buy from TD Cowen - The Globe and Mail
Anteris Announces Results for the First Quarter of 2026 - Sahm
Anteris Technologies Adds Experienced Financial Leaders to Board - The Globe and Mail
TradingKey - TradingKey
Here's Why We're Not Too Worried About Anteris Technologies Global's (ASX:AVR) Cash Burn Situation - Yahoo Finance
How Should Investors Value Anteris Technologies Global Corp (AVR - GuruFocus
Anteris Technologies appoints two directors to board - Investing.com
Anteris Technologies appoints two directors to board By Investing.com - Investing.com South Africa
Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - The Manila Times
Two experienced directors join Anteris as it advances DurAVR heart valve - Stock Titan
Anteris Technologies Reports Q1 2026 Results: $320M Raised and Key Milestones in PARADIGM Trial for DurAVR THV System - Minichart
Anteris Technologies Global Corp. Files Form 8-K for Nasdaq Listing and Company Details (May 12, 2026) - Minichart
Anteris Technologies Global adds Susan Knight and Stephen Denaro to board - Investing.com
Anteris Technologies Global Starts US PARADIGM Trial Enrolment - smallcaps.com.au
Anteris Technologies Posts Narrower Q1 Loss, Lower Net Sales - Moomoo
Why Market Is Bullish on Anteris Technologies (ASX:AVR) Today - Kalkine
Anteris adds seasoned finance leaders to board as structural heart push continues - TipRanks
Anteris Technologies Q1 2026 Results: DurAVR™ THV Trial Progresses, Cash Balance at $64.9 Million - geneonline.com
Anteris Technologies Global Corp reports results for the quarter ended March 31Earnings Summary - TradingView
AVR: DurAVRⓇ THV system adoption grows, with Q1 2026 payments to related parties at US$2.3M - TradingView
Anteris Technologies Global Corp. 1Q 2026: Revenue $494K, EPS ($0.28) — 10-Q Summary - TradingView
Anteris Technologies (Nasdaq: AVR) posts Q1 2026 loss, raises $320M for DurAVR trial - Stock Titan
Anteris Technologies Global Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Anteris Technologies Global Corp at Barclays Global Healthcare Conference Transcript - GuruFocus
Anteris Technologies Global Corp expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Anteris secures US Medicare coverage for PARADIGM Trial as DurAVR study advances | ASX:AVR, NASDAQ:AVR - Proactive financial news
Anteris treats first US patients in DurAVR pivotal trial - Yahoo Finance
Anteris Technologies Enrolls First US Patients in PARADIGM Trial; Shares Up 6% - marketscreener.com
First U.S. patients enrolled in Anteris heart valve trial By Investing.com - Investing.com South Africa
Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - The Manila Times
Anteris Technologies begins U.S. enrollment in heart valve trial - StreetInsider
First U.S. patients enter Anteris heart valve trial for stenosis - Stock Titan
Anteris Sees CDI Decline as Investors Shift to Nasdaq-Listed Common Stock - TipRanks
Sio Capital (AVR) reports 5.38M shares, 5.54% stake as of Mar 31, 2026 - Stock Titan
AVR Stock Price, Quote & Chart | ANTERIS TECHNOLOGIES GLOBAL (NASDAQ:AVR) - ChartMill
Anteris Ends v2vmedtech Development Agreement, Limits Exposure - The Globe and Mail
Anteris Technologies Global Corp (AVR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.16%
자본화:
|
볼륨(24시간):